AU2019219070B2 - Contraceptive composition with reduced cardiovascular effects - Google Patents

Contraceptive composition with reduced cardiovascular effects Download PDF

Info

Publication number
AU2019219070B2
AU2019219070B2 AU2019219070A AU2019219070A AU2019219070B2 AU 2019219070 B2 AU2019219070 B2 AU 2019219070B2 AU 2019219070 A AU2019219070 A AU 2019219070A AU 2019219070 A AU2019219070 A AU 2019219070A AU 2019219070 B2 AU2019219070 B2 AU 2019219070B2
Authority
AU
Australia
Prior art keywords
risk
estetrol
component
vte
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019219070A
Other languages
English (en)
Other versions
AU2019219070A1 (en
Inventor
Maud JOST
Glwadys RAUSIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Estetra SRL
Original Assignee
Estetra SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra SRL filed Critical Estetra SRL
Publication of AU2019219070A1 publication Critical patent/AU2019219070A1/en
Assigned to ESTETRA SRL reassignment ESTETRA SRL Amend patent request/document other than specification (104) Assignors: ESTETRA SPRL
Application granted granted Critical
Publication of AU2019219070B2 publication Critical patent/AU2019219070B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2019219070A 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects Active AU2019219070B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18155571.5 2018-02-07
EP18155571 2018-02-07
EP18160586.6 2018-03-07
EP18160586 2018-03-07
PCT/EP2019/052980 WO2019154899A1 (en) 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects

Publications (2)

Publication Number Publication Date
AU2019219070A1 AU2019219070A1 (en) 2020-09-24
AU2019219070B2 true AU2019219070B2 (en) 2024-12-19

Family

ID=65278388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019219070A Active AU2019219070B2 (en) 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects

Country Status (20)

Country Link
EP (2) EP4140489A1 (https=)
JP (2) JP2021513507A (https=)
KR (1) KR102717921B1 (https=)
CN (2) CN111683664A (https=)
AU (1) AU2019219070B2 (https=)
CA (2) CA3178181A1 (https=)
CL (1) CL2020002017A1 (https=)
EC (1) ECSP20054822A (https=)
GE (2) GEAP202215414A (https=)
IL (1) IL276584B2 (https=)
JO (1) JOP20200169A1 (https=)
MA (1) MA51733A (https=)
NZ (1) NZ766027A (https=)
PH (1) PH12020500601A1 (https=)
PY (1) PY1908892A (https=)
SG (1) SG11202007163WA (https=)
TW (1) TWI845496B (https=)
UA (1) UA126746C2 (https=)
UY (1) UY38075A (https=)
WO (1) WO2019154899A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077454A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
MD3310333T2 (ro) 2015-06-18 2020-06-30 Estetra Sprl Unitate de dozare orodispersabilă care conține un component estetrol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
DK3781171T3 (da) 2018-04-19 2022-05-02 Estetra Srl Sammensætninger og deres anvendelser til lindring af menopause-associerede symptomer
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) * 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (en) 2021-05-28 2022-12-01 Neuralis Sa Use of estetrol in treatment of respiratory infection diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018024912A1 (en) * 2016-08-05 2018-02-08 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
EP2432474A1 (de) * 2009-05-22 2012-03-28 Bayer Pharma Aktiengesellschaft Arzneimittel zur oralen verabreichung, enthaltend mindestens ein estrogen und/oder mindestens ein gestagen und mindestens einen probiotischen bakterien-stamm
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
NO3079671T3 (https=) * 2013-12-12 2018-03-24
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018024912A1 (en) * 2016-08-05 2018-02-08 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
APTER, D. et al. "Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA) Contraception (2016) vol. 94, pages 366-373 *
DAN APTER: "Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control", THE EUROPEAN JOURNAL OF CONTRACEPTION & REPRODUCTIVE HEALTH CARE *
KLUFT et al. "Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol", CONTRACEPTION, vol. 95, 2017, pages 140-147 *

Also Published As

Publication number Publication date
EP3749327A1 (en) 2020-12-16
EP4140489A1 (en) 2023-03-01
CN115429806A (zh) 2022-12-06
JP7651645B2 (ja) 2025-03-26
CN111683664A (zh) 2020-09-18
CA3178181A1 (en) 2019-08-15
CL2020002017A1 (es) 2020-12-04
WO2019154899A1 (en) 2019-08-15
IL276584B1 (en) 2024-06-01
KR102717921B1 (ko) 2024-10-16
TWI845496B (zh) 2024-06-21
UY38075A (es) 2019-10-01
ECSP20054822A (es) 2020-12-31
AU2019219070A1 (en) 2020-09-24
TW202011967A (zh) 2020-04-01
CA3089804A1 (en) 2019-08-15
PY1908892A (es) 2019-10-15
SG11202007163WA (en) 2020-08-28
GEAP202215414A (en) 2022-04-25
PH12020500601A1 (en) 2021-05-17
MA51733A (fr) 2020-12-16
JP2024009834A (ja) 2024-01-23
KR20200118464A (ko) 2020-10-15
IL276584B2 (en) 2024-10-01
UA126746C2 (uk) 2023-01-18
NZ766027A (en) 2026-03-27
JP2021513507A (ja) 2021-05-27
GEP20227407B (en) 2022-08-25
IL276584A (en) 2020-09-30
JOP20200169A1 (ar) 2020-07-07

Similar Documents

Publication Publication Date Title
AU2019219070B2 (en) Contraceptive composition with reduced cardiovascular effects
US20200046729A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
US11896602B2 (en) Method for preventing pregnancy
Klipping et al. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism
KR102780201B1 (ko) 월경통 및 생리통의 관리방법
Hee et al. Continuous use of oral contraceptives: an overview of effects and side‐effects
Stanczyk et al. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations
Klipping et al. Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
Castelli Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke
Zahradnik et al. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)—an open-label, prospective, noncontrolled, office-based Phase III study
Foidart et al. The benefits of estetrol addition to drospirenone for contraception
EP1558265A1 (en) Cardiovascular protection using anti-aldosteronic progestins
US20250360147A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
HK40081220A (en) Contraceptive composition with reduced cardiovascular effects
US7786101B2 (en) Cardiovascular protection using anti-aldosteronic progestins
EA048171B1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
EA048537B1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
RUKHLIADA et al. Visanne and Qlaira in therapy of metrorrhagic adenomyosis, leading to excessive menstrual blood loss and anemia
Pallavee et al. Peripheral arterial disease in a female using high-dose combined oral contraceptive pills
Venous Does the Progestogen Used
Shoupe et al. History Pharmacology Metabolic Effects, Side Effects and Health Benefits
Palshetkar et al. Tackling PCOS with Hormonal Contraceptives

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ESTETRA SRL

Free format text: FORMER NAME(S): ESTETRA SPRL

FGA Letters patent sealed or granted (standard patent)